Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Emergent BioSolutions Inc is a drug manufacturers-specialty & generic business based in the US. Emergent BioSolutions shares (EBS) are listed on the NYSE and all prices are listed in US Dollars. Emergent BioSolutions employs 2,200 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$49.85|
|52-week range||$49.35 - $127.20|
|50-day moving average||$53.81|
|200-day moving average||$60.80|
|Wall St. target price||$85.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$5.50|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||N/A|
|1 month (2021-09-22)||N/A|
|3 months (2021-07-26)||-20.07%|
|6 months (2021-04-26)||-22.10%|
|1 year (2020-10-26)||-47.69%|
|2 years (2019-10-25)||-9.38%|
|3 years (2018-10-26)||60.49|
|5 years (2016-10-26)||79.51%|
Valuing Emergent BioSolutions stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Emergent BioSolutions's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Emergent BioSolutions's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Emergent BioSolutions shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Emergent BioSolutions's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.55. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Emergent BioSolutions's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Emergent BioSolutions's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $604.4 million.
The EBITDA is a measure of a Emergent BioSolutions's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.7 billion|
|Operating margin TTM||28.68%|
|Gross profit TTM||$857.6 million|
|Return on assets TTM||11.38%|
|Return on equity TTM||21.82%|
|Market capitalisation||$2.7 billion|
TTM: trailing 12 months
There are currently 3.3 million Emergent BioSolutions shares held short by investors – that's known as Emergent BioSolutions's "short interest". This figure is 1.9% down from 3.3 million last month.
There are a few different ways that this level of interest in shorting Emergent BioSolutions shares can be evaluated.
Emergent BioSolutions's "short interest ratio" (SIR) is the quantity of Emergent BioSolutions shares currently shorted divided by the average quantity of Emergent BioSolutions shares traded daily (recently around 416656.8877551). Emergent BioSolutions's SIR currently stands at 7.84. In other words for every 100,000 Emergent BioSolutions shares traded daily on the market, roughly 7840 shares are currently held short.
However Emergent BioSolutions's short interest can also be evaluated against the total number of Emergent BioSolutions shares, or, against the total number of tradable Emergent BioSolutions shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Emergent BioSolutions's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Emergent BioSolutions shares in existence, roughly 60 shares are currently held short) or 0.0754% of the tradable shares (for every 100,000 tradable Emergent BioSolutions shares, roughly 75 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Emergent BioSolutions.
Find out more about how you can short Emergent BioSolutions stock.
We're not expecting Emergent BioSolutions to pay a dividend over the next 12 months.
Over the last 12 months, Emergent BioSolutions's shares have ranged in value from as little as $49.35 up to $127.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Emergent BioSolutions's is 1.0249. This would suggest that Emergent BioSolutions's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Emergent BioSolutions Inc. , a life sciences company, focuses on the provision of preparedness and response products and solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; and Trobigard, a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG for the treatment of SARS-CoV-2; FLU-IGIV for the treatment of seasonal influenza A virus; AV7909, an anthrax vaccine candidate; CHIKV VLP, a chikungunya virus VLP vaccine; ZIKV-IG, a zika therapeutic candidate; Shigella-ETEC, a shigella vaccine expressing ETEC antigens; EBS-LASV, a vector vaccine for Lassa fever; UNI-FLU, a universal influenza vaccine; rVSV-Marburg, a vector vaccine for treatment of Marburg virus disease; rVSV-Sudan, a vector vaccine for treatment of Sudan virus disease; DAT, a diphtheria antitoxin; Ricin-IG, a ricin antitoxin; and Pan-Ebola, a Ebola/Sudan monoclonal.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.